The assessment of early response in vivo is a further advantage of NACT, allowing personalized treatment changes and providing individualized post-treatment informations on prognosis for possible additional adjuvant therapy; this is the case especially for patients with human epidermal growth factor receptor 2 (HER2) positive and triple negative breast cancer [5]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.